Insights+: EMA Marketing Authorization of New Drugs in January 2024

Shots: The EMA approved 2 BLA and 6 New Chemical Entities in January 2024, leading to treatments for patients and advances in the healthcare industry In January 2024, the major highlighted drugs were Padcev to treat Bladder Cancer and Eylea for the treatment of Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) PharmaShots has…

BySenior EditorFebruary 21, 2024

News

Bayer and Regeneron Receive the EC’s Approval for Eylea (aflibercept, 8mg) for the Treatment of Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Shots: The approval was granted based on the results from the P-III (PULSAR) & P-II/III (PHOTON) clinical trials evaluating the safety & efficacy of Eylea 8mg vs 2mg dosed Q8W following initial monthly dosing in patients (N=1,164) with nAMD & DME. The 1EP of both the studies was non-inferior BCVA changes Both the studies met…

ByDipanshu DixitJanuary 8, 2024

TOP 20

Top 20 Prescription Drugs Based on 2022 Total Revenue

Shots: Prescription drugs have an instrumental role in effectively controlling chronic diseases like heart-related conditions, diabetes, arthritis, hypertension, and cancer, among others. Unlike over-the-counter drugs, prescription drugs are advised not to be taken without the authorization of a doctor In 2022, the global market size of prescription drugs was worth $1035.5B and is envisioned to…

ByPrince GiriNovember 21, 2023

TOP 20

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Shots: Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and research In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…

ByPrince GiriSeptember 26, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2023

Shots: The US FDA approved 5 NDAs and 5 BLA in February 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 19 novel products in 2023 In February 2023, the major highlights drugs were, Tezspire (tezepelumab) approval for severe asthma, Altuviiio for hemophilia A PharmaShots has compiled…

BySenior EditorMarch 15, 2023

INSIGHTS+

Disease of the Month: Age-Related Macular Degeneration

Introduction: AMD, an eye disease that can cause of loss of eyesight/blur vision mostly in people ≥50 years of age and it is the leading cause of visual impairment worldwide. It occurs when the part of the retina (macula) is damaged. Patients lose their central vision and cannot see fine details The three stages of…

BySenior EditorFebruary 9, 2023

TOP 20

Top 20 Prescription Drugs Based on 2021 Total Revenue

Shots: The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…

ByPrince GiriNovember 10, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Humira (April Edition)

Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…

BySenior EditorApril 29, 2022

INSIGHTS+

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years. No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…

BySenior EditorApril 28, 2022

Insights+: EMA Marketing Authorization of New Drugs in January 2024

Top 20 Prescription Drugs Based on 2022 Total Revenue

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Insights+: The US FDA New Drug Approvals in February 2023

Disease of the Month: Age-Related Macular Degeneration

Top 20 Prescription Drugs Based on 2021 Total Revenue

Top Performing Drug of 2021 – Humira (April Edition)

Top Performing Drugs of 2021: A Monthly Series by PharmaShots

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter